ZIPRASIDONE MESYLATE - Generic Drug Details

What are the generic sources for ziprasidone mesylate and what is the scope of patent protection?

Ziprasidone mesylate is the generic ingredient in two branded drugs marketed by Viatris, Gland, MSN, and Steriscience, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

Eight suppliers are listed for this compound.

Summary for ZIPRASIDONE MESYLATE

US Patents:	0
Tradenames:	2
Applicants:	4
NDAs:	4
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	39
Clinical Trials:	1
Patent Applications:	387
What excipients (inactive ingredients) are in ZIPRASIDONE MESYLATE?	ZIPRASIDONE MESYLATE excipients list
DailyMed Link:	ZIPRASIDONE MESYLATE at DailyMed

Recent Clinical Trials for ZIPRASIDONE MESYLATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pfizer	Phase 4
Yang Fude	Phase 4

See all ZIPRASIDONE MESYLATE clinical trials

Pharmacology for ZIPRASIDONE MESYLATE

Drug Class

Atypical Antipsychotic

Anatomical Therapeutic Chemical (ATC) Classes for ZIPRASIDONE MESYLATE

N05AE	Indole derivatives
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for ZIPRASIDONE MESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	GEODON	ziprasidone mesylate	POWDER;INTRAMUSCULAR	020919-001	Jun 21, 2002	AP	RX	Yes	Yes
Steriscience	ZIPRASIDONE MESYLATE	ziprasidone mesylate	POWDER;INTRAMUSCULAR	217595-001	Sep 3, 2025	AP	RX	No	No
Gland	ZIPRASIDONE MESYLATE	ziprasidone mesylate	POWDER;INTRAMUSCULAR	211908-001	Dec 26, 2019	AP	RX	No	No
Msn	ZIPRASIDONE MESYLATE	ziprasidone mesylate	POWDER;INTRAMUSCULAR	216091-001	Sep 15, 2022	AP	RX	No	No

Expired US Patents for ZIPRASIDONE MESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	GEODON	ziprasidone mesylate	POWDER;INTRAMUSCULAR	020919-001	Jun 21, 2002
Viatris	GEODON	ziprasidone mesylate	POWDER;INTRAMUSCULAR	020919-001	Jun 21, 2002
Viatris	GEODON	ziprasidone mesylate	POWDER;INTRAMUSCULAR	020919-001	Jun 21, 2002
Viatris	GEODON	ziprasidone mesylate	POWDER;INTRAMUSCULAR	020919-001	Jun 21, 2002

Market Dynamics and Financial Trajectory of ZIPRASIDONE MESYLATE

Last updated: January 9, 2026

Executive Summary

Ziprasidone mesylate, marketed primarily under the brand name Geodon among others, is a second-generation antipsychotic (SGA) indicated for schizophrenia and bipolar disorder. The drug has maintained a considerable presence within the neuropsychiatric segment, driven by its efficacy profile and comparable side effect spectrum relative to alternatives. This report analyzes the current market landscape, key drivers, competitive positioning, and future financial prospects.

Introduction: Overview of ZIPRASIDONE MESYLATE

Ziprasidone mesylate debuted in the early 2000s, approved by the U.S. Food and Drug Administration (FDA) in 2001. Its mechanism involves antagonism of dopamine D2 and serotonin 5-HT2A receptors, with additional affinity for various serotonergic receptors, contributing to its antipsychotic effects.

Therapeutic Indications

• Schizophrenia
• Bipolar I disorder (manic or mixed episodes)

Key Specifications

Parameter	Details
Formulation	Oral capsules, injectable (intramuscular)
Typical Dosage	20-80 mg/day (oral)
Onset of Action	1-2 hours orally; rapid IM injections
Common Side Effects	Drowsiness, nausea, dizziness, QT prolongation

Market Landscape: Size and Segmentation

Global Market Valuation (2022–2027 Forecast)

Region	Market Size (USD Million)	CAGR (2022-2027)	Notes
North America	1,600	3.2%	Dominant with high penetration and insurance coverage
Europe	850	2.8%	Growing awareness and early adoption
Asia-Pacific	400	6.5%	Rapid market expansion and unmet needs
Rest of World	150	4.0%	Emerging markets

Total Market (2022): Approx. USD 3.0 billion

Market Segmentation

• Indication-wise
  • Schizophrenia: ~65%
  • Bipolar Disorder: ~35%
• Formulation-wise
  • Oral tablets: 80%
  • Injectable: 20%
• Distribution channel-wise
  • Hospitals: 60%
  • Specialty clinics: 25%
  • Retail pharmacies: 15%

Key Market Players

Company	Product(s)	Market Share (%)	Notes
Pfizer	Geodon (brand)	40	Leading in North America
Mylan (now part of Viatris)	Generic ziprasidone	25	Growing market share
Teva	Generic formulations	15	Expanding presence
Others	Various	20	Regional players

Market Drivers and Challenges

Drivers

1. High Efficacy and Tolerability Profile
   • Similar efficacy to risperidone, olanzapine
   • Lower metabolic side effects, leading to preference (FDA labeling)
2. Expanding Indications
   • Off-label uses in agitation, irritability in autism, and schizoaffective disorders
3. Generic Entry and Cost Advantages
   • Patent expirations (Pfizer’s patent expired in 2016) resulted in intense generic competition, reducing prices
4. Increased Adoption in Emerging Markets
   • Growing mental health awareness and healthcare infrastructure

Challenges

1. QTc Prolongation Risks
   • Boxed warning limits in some markets cause hesitancy
2. Competitive Landscape
   • Dominance of risperidone, olanzapine, and aripiprazole
3. Side Effect Profile Compared to Newer Agents
   • Limited efficacy in treatment-resistant cases
4. Regulatory and Reimbursement Dynamics
   • Variability in acceptance and reimbursement policies

Financial Trajectory and Revenue Trends

Historical Revenue & Sales Data

Year	Pfizer (USD Millions)	Generic Market Revenue	Comments
2016	650	N/A	Patent expiry leads to decline in branded sales
2018	250	400	Generics capture market share
2020	150	250	Market saturation, competition intensifies
2022	120	200	Stabilization at lower levels

Note: The decline post-2016 reflects patent expiry and proliferation of generics. Despite reduced market share, ziprasidone remains a relevant entrant due to ongoing demand.

Forecasted Revenue (2023–2027)

Year	Estimated Global Revenue (USD Millions)	Growth Drivers
2023	120	Steady market, increased generic availability
2024	125	Slight market recovery, emerging markets growth
2025	130	Market saturation, new formulation launches?
2026	135	Expanded indications, ongoing competition
2027	140	Modular growth, potential biosimilars in development

Assumption: Mild CAGR of approximately 1.5% reflects stabilizing sales; however, emerging markets could alter this trajectory.

Competitive and Regulatory Environment

Generic Drug Proliferation

• Patent status: Patent expired in key markets, enabling generics.
• Market share capture: Generic formulators now hold 60–70% of sales worldwide.
• Pricing dynamics: Price erosion observed; average retail price halved post-patent expiry.

Regulatory News & Policies

• FDA (2022): No significant new restrictions; ongoing monitoring for QT effects.
• EMA & other agencies: Similar regulatory landscape, with emphasis on safety data.
• Reimbursement Policies: Reimbursed widely in developed markets, with variable coverage in emerging regions.

Technological Innovations

• No recent blockbuster formulations or delivery innovations specifically for ziprasidone.
• Potential future research into long-acting injectables or formulations with reduced side effects.

Comparative Analysis with Similar Agents

Agent	Mechanism	Indications	Market Share (%)	Side Effect Profile	Patent Status
Risperidone	D2/5-HT2A antagonist	Schizophrenia, bipolar	35	Metabolic concerns	Expired 2019
Olanzapine	D2/5-HT2A, Muscarinic	Schizophrenia, bipolar	30	Weight gain, diabetes risk	Expired 2011 (patent)
Aripiprazole	D2 partial agonist	Schizophrenia, bipolar	20	Akathisia, insomnia	Patents expire 2029-2035
Ziprasidone	D2/5-HT2A antagonism	Schizophrenia, bipolar	5–10	QT prolongation, sedation	Expired in key markets

Analysis: Ziprasidone's market share is notably smaller, partly due to safety concerns and competition. Nonetheless, niche positioning and safety profile may foster continued demand.

Future Outlook and Strategic Opportunities

Potential Growth Avenues

• Regional Expansion: Targeted marketing in Asia-Pacific, Latin America.
• Formulation Innovation: Extended-release formulations or depot injections.
• Combination Therapy: Co-formulations with mood stabilizers.
• Digital & Monitoring Tools: ECG monitoring devices to mitigate QT risks, improving safety profiles.

Risks to Financial Trajectory

• Emergence of novel antipsychotics with superior safety and efficacy profiles.
• Regulatory restrictions due to safety concerns.
• Pricing pressures from aggressive generic competition.

Key Takeaways

• Market Maturity: Post-patent expiry, ziprasidone faces intense generic competition, leading to revenues declining and stabilizing at lower levels.
• Growth Potential: Limited near-term growth; future prospects depend on regional expansion, formulations, and safety management.
• Competitive Positioning: Maintains relevance in niches requiring an antipsychotic with a relatively favorable metabolic profile but must differentiate through safety optimizations.
• Strategic Focus: Companies should explore combination therapies, technological innovations, and emerging markets to prolong the financial trajectory.
• Regulatory Navigations: Monitoring QT safety issues remains critical, with developments influencing market access and reimbursement.

FAQs

1. What are the primary factors influencing ziprasidone's market share?
   Its efficacy, safety profile—particularly QT prolongation risks—and competition from other SGAs are key influences. Post-patent expiration, generic proliferation has significantly reduced its market share.

2. How does ziprasidone compare to other antipsychotics in safety?
   It has a relatively lower metabolic risk but poses a higher risk for QT prolongation, necessitating ECG monitoring in certain patient populations.

3. Is ziprasidone seeing growth in emerging markets?
   Yes; because of cost benefits and increasing mental health awareness, emerging markets are increasingly adopting generic ziprasidone formulations.

4. Are there innovations or new formulations in development for ziprasidone?
   Currently, no major innovations have been registered; however, research into longer-acting formulations or improved safety profiles warrants watchfulness.

5. What is the outlook for ziprasidone's revenue over the next five years?
   The revenue is expected to stabilize, with minimal growth around 1–2% annually, contingent on regional expansion and possible new formulations.

---

References

[1] Pfizer Annual Reports (2016–2022)
[2] Market Research Future, “Global Antipsychotics Market,” 2022
[3] FDA Drug Approvals Database, 2001–2022
[4] IQVIA Data on Generic Drug Penetration, 2022
[5] EMA Drug Safety Updates, 2022